Cargando…
Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
Background: The timing of imaging for (68)gallium ((68)Ga)-PSMA and (68)Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: W...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136247/ https://www.ncbi.nlm.nih.gov/pubmed/37189670 http://dx.doi.org/10.3390/biomedicines11041052 |
_version_ | 1785032171956731904 |
---|---|
author | Librizzi, Damiano Eilsberger, Friederike Ottenthaler, Stefan Ebrahimifard, Ali Luster, Markus Yousefi, Behrooz H. |
author_facet | Librizzi, Damiano Eilsberger, Friederike Ottenthaler, Stefan Ebrahimifard, Ali Luster, Markus Yousefi, Behrooz H. |
author_sort | Librizzi, Damiano |
collection | PubMed |
description | Background: The timing of imaging for (68)gallium ((68)Ga)-PSMA and (68)Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: We retrospectively evaluated 112 patients who underwent (68)Ga-DOTATOC-PET/CT and 82 patients who underwent (68)Ga-PSMA-PET/CT. The first scan was acquired 60 min (±15 min) after application. In cases of diagnostic ambiguity, a second scan was performed 30–60 min later. Pathological lesions were analyzed. Results: Almost half of all (68)Ga-DOTATOC cases and about one-third of all (68)Ga-PSMA examinations showed a change in findings due to the second acquisition. In total, 45.5% of neuroendocrine tumor (NET) patients and 66.7% of prostate cancer (PCa) patients showed relevant TNM classification changes. For (68)Ga-PSMA, there were significant increases in sensitivity and specificity from 81.8% to 95.7% and from 66.7% to 100%, respectively. Statistically significant improvements in sensitivity (from 53.3% to 93.3%) and specificity (from 54.6% to 86.4%) were demonstrated for NET patients. Conclusion: Early second images can improve diagnostics with (68)Ga-DOTATOC and (68)Ga-PSMA PET/CT. |
format | Online Article Text |
id | pubmed-10136247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101362472023-04-28 Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors Librizzi, Damiano Eilsberger, Friederike Ottenthaler, Stefan Ebrahimifard, Ali Luster, Markus Yousefi, Behrooz H. Biomedicines Article Background: The timing of imaging for (68)gallium ((68)Ga)-PSMA and (68)Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: We retrospectively evaluated 112 patients who underwent (68)Ga-DOTATOC-PET/CT and 82 patients who underwent (68)Ga-PSMA-PET/CT. The first scan was acquired 60 min (±15 min) after application. In cases of diagnostic ambiguity, a second scan was performed 30–60 min later. Pathological lesions were analyzed. Results: Almost half of all (68)Ga-DOTATOC cases and about one-third of all (68)Ga-PSMA examinations showed a change in findings due to the second acquisition. In total, 45.5% of neuroendocrine tumor (NET) patients and 66.7% of prostate cancer (PCa) patients showed relevant TNM classification changes. For (68)Ga-PSMA, there were significant increases in sensitivity and specificity from 81.8% to 95.7% and from 66.7% to 100%, respectively. Statistically significant improvements in sensitivity (from 53.3% to 93.3%) and specificity (from 54.6% to 86.4%) were demonstrated for NET patients. Conclusion: Early second images can improve diagnostics with (68)Ga-DOTATOC and (68)Ga-PSMA PET/CT. MDPI 2023-03-29 /pmc/articles/PMC10136247/ /pubmed/37189670 http://dx.doi.org/10.3390/biomedicines11041052 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Librizzi, Damiano Eilsberger, Friederike Ottenthaler, Stefan Ebrahimifard, Ali Luster, Markus Yousefi, Behrooz H. Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors |
title | Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors |
title_full | Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors |
title_fullStr | Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors |
title_full_unstemmed | Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors |
title_short | Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors |
title_sort | diagnostic impact of dual-time pet/ct with (68)gallium-psma in prostate cancer and (68)gallium-dotatoc in neuroendocrine tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136247/ https://www.ncbi.nlm.nih.gov/pubmed/37189670 http://dx.doi.org/10.3390/biomedicines11041052 |
work_keys_str_mv | AT librizzidamiano diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors AT eilsbergerfriederike diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors AT ottenthalerstefan diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors AT ebrahimifardali diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors AT lustermarkus diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors AT yousefibehroozh diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors |